

21 Rec'd PCT/ 07 APR 1997

FORM PTO-1390 (Modified) (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		53466/200 U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <b>08/817084</b>	
INTERNATIONAL APPLICATION NO. <b>PCT/JP95/01144</b>	INTERNATIONAL FILING DATE <b>June 7, 1995</b>	PRIORITY DATE CLAIMED <b>October 7, 1994</b>	
TITLE OF INVENTION <b>CHRONIC RHEUMATOID ARTHRITIS THERAPY CONTAINING IL-6 ANTAGONIST AS EFFECTIVE COMPONENT</b>			
APPLICANT(S) FOR DO/EO/US <b>Tadamitsu KISHIMOTO, Masahiko MIHARA, Yoichiro MORIYA and Yoshiyuki OHSUGI</b>			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</li> </ol> </li> <li>6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371 (c)(2)).</li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>			
Items 11. to 16. below concern other document(s) or information included:			
<ol style="list-style-type: none"> <li>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</li> <li>14. <input type="checkbox"/> A substitute specification.</li> <li>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>16. <input type="checkbox"/> Other items or information:</li> </ol>			

08817084 040797

PCT/JP95/01144

53466/200

17. ☒ The following fees are submitted:**Basic National Fee (37 CFR 1.492(a)(1)-(5):**

Search Report has been prepared by the EPO or JPO ..... \$910.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)

..... \$700.00

No international preliminary examination fee paid to USPTO (37 CFR 1.482)

but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ..... \$770.00

Neither international preliminary examination fee (37 CFR 1.482) nor

international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$1040.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)

and all claims satisfied provisions of PCT Article 33(2)-(4) ..... \$96.00

**ENTER APPROPRIATE BASIC FEE AMOUNT =****CALCULATIONS**

PTO USE ONLY

**910.00**Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(e))

Claims	Number Filed	Number Extra	Rate
Total Claims	8	-20 =	0
Independent Claims	2	-3 =	0
Multiple dependent claim(s) (if applicable)			+ \$260.00
<b>TOTAL OF ABOVE CALCULATIONS</b>			<b>= \$ 910.00</b>

Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement

must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).

**SUBTOTAL = \$ 910.00**Processing fee of \$130.00 for furnishing English translation later the ☐ 20 ☐ 30

months from the earliest claimed priority date (37 CFR 1.492(f)).

**TOTAL NATIONAL FEE = \$ 910.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be

accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

**TOTAL FEES ENCLOSED = \$ 950.00**a. ☒ A check in the amount of \$950.00 to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. 19-0741 in the amount of \$\_\_\_\_\_ to the above fees. A duplicate copy of this sheet is enclosed.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0741. A duplicate copy of this sheet is enclosed.**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Foley & Lardner  
3000 K Street, N.W., Suite 500  
P.O. Box 25696  
Washington, D.C. 20007-8696

SIGNATURE

NAME

25,258

REGISTRATION NUMBER

## DESCRIPTION

Chronic Rheumatoid Arthritis Therapy Containing IL-6  
Antagonist as Effective Component

5

## TECHNICAL FIELD

The present invention relates to a chronic  
rheumatoid arthritis therapy or synovial cell growth  
inhibitor comprising an interleukin-6 antagonist as an  
effective component.

10

## BACKGROUND ART

Chronic rheumatoid arthritis is a systemic chronic  
inflammatory disease in which abnormal growth of  
connective tissue, including synovial tissue, occurs in  
the joints (Melnik et al., Arthritis Rheum. 33: 493-500,  
1990). The joints of chronic rheumatoid arthritis  
patients have been shown to have marked growth of  
synovial cells, formation of a multilayer structure due  
to abnormal growth of the synovial cells (pannus  
formation), invasion of the synovial cells into cartilage  
tissue and bone tissue, vascularization toward the  
synovial tissue, and infiltration of inflammatory cells  
such as lymphocytes and macrophages. Mechanisms of onset  
of chronic rheumatoid arthritis have been reported to be  
based on such factors as heredity, bacterial infection  
and the contribution of various cytokines and growth  
factors, but the overall mechanism of onset has remained  
unclear.

15

20

25

In recent years, cytokines and growth factors  
including interleukin-1 (IL-1), interleukin-8 (IL-8),  
tumor necrosis factor  $\alpha$  (TNF $\alpha$ ), transforming growth  
factor  $\beta$  (TGF $\beta$ ), fibroblast growth factor (FGF) and  
platelet-derived growth factor (PDGF) have been detected  
in the synovial membrane and synovial fluid of chronic  
rheumatoid arthritis patients (Nouri et al., Clin. Exp.  
Immunol. 55:295-302, 1984; Thornton et al., Clin. Exp.  
Immunol. 86:79-86, 1991; Saxne, et al., Arthritis Rheum.

30

35

08817084 04059  
252040 48021880

31:1041-1045, 1988; Seitz et al., J. Clin. Invest. 87:463-469, 1991; Lafyatis et al., J. Immunol. 143:1142-1148, 1989; Melnyk et al., Arthritis Rheum. 33:493-500, 1990).

5           It is believed that IL-1, TNF $\alpha$  and PDGF are particularly powerful synovial cell growth factors (Thornton et al., Clin. Exp. Immunol. 86:79-86, 1991; Lafyatis et al., J. Immunol. 143:1142-1148, 1989; Gitter et al., Immunology 66:196-200, 1989). It has also been  
10 suggested that stimulation by IL-1 and TNF results in production of interleukin-6 (IL-6) by synovial cells (Ito et al., Arthritis Rheum. 35:1197-1201, 1992).

IL-6 is a cytokine also known as B cell-stimulating factor 2 or interferon  $\beta$ 2. IL-6 was discovered as a  
15 differentiation factor contributing to activation of B lymphoid cells (Hirano, T. et al., Nature 324, 73-76, 1986), and was later found to be a multifunction cytokine which influences the functioning of a variety of different cell types (Akira, S. et al., Adv. in  
20 Immunology 54, 1-78, 1993). Two functionally different membrane molecules are necessary for the induction of IL-6 activities. One of those is IL-6 receptor (IL-6R), an approximately 80 KD molecular weight, which binds specifically to IL-6.

25           IL-6R exists in a membrane-binding form which is expressed on the cell membrane and penetrates the cell membrane, as well as in the form of soluble IL-6R (sIL-6R) which consists mainly of the extracellular domain. Another protein is gp130 with a molecular weight of  
30 approximately 130 KD, which is non-ligand-binding but rather functions to mediate signal transduction. IL-6 and IL-6R form the complex IL-6/IL-6R which in turn binds with another membrane protein gp130, to induce the biological activity of IL-6 to the cell (Taga et al., J.  
35 Exp. Med. 196:967, 1987).

It has been reported that the serum or synovial fluid of chronic rheumatoid arthritis patients contains

0837084 0409

excessive amounts of interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6R) (Houssiau et al., Arthritis Rheum. 31:784-788, 1988; Hirano et al., Eur. J. Immunol. 18:1797-1801, 1988; Yoshioka et al., Japn. J. Rheumatol. in press), and since similar results have also been obtained in rheumatoid arthritis animal models (Takai et al., Arthritis Rheum. 32:594-600, 1989; Leisten et al. Clin. Immunol. Immunopathol. 56: 108-115, 1990), it has been suggested that IL-6 is somehow involved in chronic rheumatoid arthritis.

However, Japanese Unexamined Patent Publication No. 4-89433 discloses that peptides which strongly promote IL-6 production are effective as therapies for chronic rheumatoid arthritis.

Also, Higaki et al. have suggested that synovial cells from chronic rheumatoid arthritis patients have a low growth reaction against IL-6, and that IL-6 thus has an inhibitory function against growth of synovial cells (Clinical Immunology, 22:880-887, 1990). Thus, conflicting reports exist regarding the relationship between IL-6 and chronic rheumatoid arthritis, and the relationship is as yet unclear.

Recently, Wendling et al. have reported that administration of anti-IL-6 antibodies to chronic rheumatoid arthritis patients temporarily alleviates the clinical and biological symptoms, while also increasing IL-6 levels in the serum (J. Rheumatol. 20:259-262, 1993).

These reports provide no data at all about whether IL-6 accelerates growth of chronic rheumatoid arthritis synovial cells or has an inhibitory effect, and thus it is still unknown whether or not IL-6 has a direct effect on synovial cells of chronic rheumatoid arthritis patients.

#### DISCLOSURE OF THE INVENTION

Anti-inflammatory steroidal agents such as corticosteroids have been used as rheumatoid arthritis

therapies, but since their continuous use induces undesirable side effects such as skin tissue damage and inhibition of adrenal cortex function, drugs with less side effects have been sought.

5           It is an object of the present invention to provide a novel chronic rheumatoid arthritis therapy without the disadvantages mentioned above. More specifically, the present invention provides a pharmaceutical composition for inhibiting abnormal growth of synovial cells in  
10 chronic rheumatoid arthritis, whose effective component is an interleukin-6 antagonist, as well as a pharmaceutical composition for treatment of a chronic rheumatoid arthritis having the same effect.

          The present inventors have conducted diligent  
15 research on the role of IL-6 on synovial cells from rheumatoid arthritis, during which no growth of chronic rheumatoid arthritis synovial cells was found with IL-6 alone and a factor other than IL-6 was therefore investigated, and this has resulted in completion of the  
20 present invention based on the discovery that while IL-6 alone exhibits almost no growth effect on synovial cells, a powerful synovial cell growth effect occurs in the presence of both IL-6 and soluble IL-6R, and further that this synovial cell growth effect is suppressed by  
25 addition of an antagonist which inhibits IL-6 activity, such as IL-6 antibody or IL-6R antibody.

          In other words, the present invention relates to a pharmaceutical composition for treatment of a chronic rheumatoid arthritis comprising an IL-6 antagonist as the  
30 effective component. More specifically, the present invention relates to a pharmaceutical composition for treatment of a chronic rheumatoid arthritis comprising an IL-6 antagonist as the effective component and suppressing abnormal growth of synovial cells. The  
35 present invention also relates to a synovial cell growth inhibitor whose effective component is an IL-6 antagonist.

08817084-0409  
462010-18021880

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph showing  $^3\text{H}$ -thymidine uptake into synovial cells in the presence of either IL-6 or sIL-6R alone and in the presence of both IL-6 and sIL-6R.

Fig. 2 is a graph showing the effect of IL-6 antibody or IL-6R antibody on  $^3\text{H}$ -thymidine uptake into synovial cells in the presence of both IL-1 $\beta$  and sIL-6R.

Fig. 3 is a graph showing the effect of IL-6 antibody or IL-6R antibody on  $^3\text{H}$ -thymidine uptake into synovial cells in the presence of both IL-6 and sIL-6R.

Fig. 4 is a graph showing the suppressive effect of IL-6R antibody on the onset of mouse collagen-induced arthritis models.

Fig. 5 is a graph showing serum anti-collagen antibody levels in arthritic mice.

Fig. 6 is a photograph of histopathological examination of hind paw joint of a collagen-arthritis mouse. (a) is a photograph from a mouse in an IL-6 receptor antibody-administered group, and (b) is from a mouse in a control antibody-administered group. In the IL-6 receptor antibody-administered group, invasion of granulation tissue into the cartilage and bone (chronic proliferative synovitis) was clearly suppressed.

#### DETAILED DESCRIPTION OF THE INVENTION

A pharmaceutical composition for treatment of a chronic rheumatoid arthritis according to the invention is a drug which when administered to chronic rheumatoid arthritis patients suppresses growth of synovial cells in joints and has an alleviating and therapeutic effect on the symptoms.

The IL-6 antagonist used according to the invention may be derived from any source so long as it is a substance which blocks IL-6 signal transfer and inhibits IL-6 biological activity. IL-6 antagonists include IL-6 antibody, IL-6R antibody, gp130 antibody, modified IL-6, antisense IL-6R and partial peptides of IL-6 or IL-6R.

An antibody used as an antagonist according to the invention, such as IL-6 antibody, IL-6R antibody or gp130 antibody, may be of any derivation or type (monoclonal, polyclonal), but monoclonal antibodies derived from mammalian animals are especially preferred. These antibodies bind to IL-6, IL-6R or gp130 to inhibit binding between IL-6 and IL-6R or IL-6R and gp130 and thus block IL-6 signal transduction, inhibiting IL-6 biological activity.

The animal species for the monoclonal antibody-producing cells is not particularly limited so long as it is a mammal, and human antibodies or antibodies derived from a mammal other than human may be used. Monoclonal antibodies derived from a mammal other than human are preferably monoclonal antibodies derived from rabbits or rodents because they are easier to prepare. There is no particular restriction on the rodents, but preferred examples are mice, rats and hamsters.

Examples of such antibodies which are IL-6 antibodies include MH166 (Matsuda et al., Eur. J. Immunol. 18:951-956, 1988) and SK2 antibody (Sato et al., Journal for the 21st General Meeting of the Japan Immunology Association, 21:116, 1991). Examples of IL-6R antibodies include PM-1 antibody (Hirata et al., J. Immunol. 143:2900-2906, 1989), AUK12-20 antibody, AUK64-7 antibody and AUK146-15 antibody (Intl. Unexamined Patent Application No. WO92-19759). An example of gp130 antibody is AM64 antibody (Japanese Unexamined Patent Publication No. 3-219894).

Among these, PM-1 antibody is preferred.

Monoclonal antibodies may be prepared in the following manner which is based on a known technique. That is, IL-6, IL-6R or gp130 is used as the sensitizing antigen for immunization according to a conventional immunizing method, and the resulting immunocytes are then fused with known parent cells by a conventional cell fusion method and monoclonal antibody-producing cells are



screened by a conventional screening method to prepare the antibodies.

More specifically, the monoclonal antibodies may be prepared in the following manner. For example, if the sensitizing antigen is human IL-6, the antibodies are obtained using the gene sequence for human IL-6 disclosed by Hirano et al., Nature, 324:73, 1986. The human IL-6 gene sequence is inserted into a publicly expression vector system and used to transform suitable host cells, after which the desired IL-6 protein is purified from the host cells or from the culture supernatant and the purified IL-6 protein is then used as the sensitizing antigen.

In the case of human IL-6R, the IL-6R protein may be obtained by the same method as for human IL-6 described above, using the gene sequence disclosed in European Patent Application No. EP325474. Two types of IL-6R exist, one expressed on the cell membrane and a soluble form (sIL-6R) which is separated from the cell membrane. sIL-6R consists mainly of the extracellular domain of IL-6R which is attached to the cell membrane, and it differs from the membrane-bound IL-6R in that it lacks the transmembrane domain or the transmembrane domain and the intracellular domain.

In the case of human gp130, the gp130 protein may be obtained by the same method as for human IL-6 described above, using the gene sequence disclosed in European Patent Application No. EP411946.

The mammalian animals immunized with the sensitizing antigen are not particularly restricted, but they are preferably selected in consideration of their compatibility with the parent cells used for the cell fusion, and generally mice, rats, hamsters and rabbits may be used.

The immunization of the animals with the sensitizing antigen may be accomplished by a publicly known method. For example, a conventional method involves

intraperitoneal or subcutaneous injection of the mammalian animals with the sensitizing antigen. Specifically, the sensitizing antigen is preferably diluted with an equivalent of PBS (Phosphate-Buffered Saline) or physiological saline, suspended and used together with a suitable amount of a conventional adjuvant such as Freund's complete adjuvant if desired, and then administered to the mammalian animals a few times every 4-21 days. An appropriate carrier may also be used for immunization with the sensitizing antigen.

After this immunization and confirmation of increased serum levels of the desired antibody, immunocytes are taken from the mammalian animals and supplied for cell fusion, with especially preferred immunocytes being splenic cells.

The parent cells used for fusion with the above-mentioned immunocytes may be myeloma cells from mammalian animals, and a number of already publicly known cell strains may be suitably used, including P3 (P3x63Ag8.653) (J. Immunol. 123:1548, 1978), p3-U1 (Current Topics in Microbiology and Immunology 81:1-7, 1978), NS-1 (Eur. J. Immunol. 6:511-519, 1976), MPC-11 (Cell, 8:405-415, 1976), SP2/0 (Nature, 276:269-270, 1978), Of (J. Immunol. Meth. 35:1-21, 1980), S194 (J. Exp. Med. 148:313-323, 1978), R210 (Nature, 277:131-133, 1979). The cell fusion of the immunocytes with the myeloma cells may be based on a publicly known method, for example the method of Milstein et al. (Milstein et al., Methods Enzymol. 73:3-46, 1981).

More specifically, the above-mentioned cell fusion is carried out in a conventional nutrient culture in the presence of a cell fusion promoter. The fusion promoter used may be, for example, polyethylene glycol (PEG) or Sendai virus (HVJ), and if desired an aid such as dimethylsulfoxide may also be added to increase the fusion efficiency.

The proportions of the immunocytes and myeloma cells

08817084-04079  
262070-48027880

used are preferably a 1- to 10-fold amount of immunocytes with respect to the myeloma cells. The culturing medium used for the cell fusion may be, for example, RPMI1640 culture medium or MEM culture medium which are suitable for growth of myeloma cell strains, or other common culturing media used for such cell culturing, and supplementary serum solutions such as fetal calf serum (FCS) may also be used therewith.

The cell fusion is carried out by thoroughly mixing the prescribed amounts of the immunocytes and the myeloma cells in the culture medium described above, adding a PEG solution preheated to about 37°C, for example with PEG having an average molecular weight of about 1000 to 6000, to the culture medium usually at a concentration of 30 to 60% (w/v), and then mixing to form the desired fused cells (hybridomas). Next, the procedure of gradual addition of a suitable culture medium and centrifugation to remove the supernatant is repeated, to accomplish removal of the cell fusing agent, etc. which is unfavorable for growth of the hybridomas.

Suitable hybridomas are selected by culturing in a normal selective culture medium, such as HAT culture medium (containing hypoxanthine, aminopterin and thymine). The culturing in the HAT culture medium is continued for a given time, usually a few days to a few weeks, sufficient for death of the cells other than the hybridomas (non-fused cells). Next, normal limited dilution is carried out, and the hybridomas producing the desired antibodies are subjected to masking and monocloning.

The monoclonal antibody-producing hybridomas prepared in this manner may be subcultured in a common culture solution and they may also be placed in liquid nitrogen for long-term storage.

In order to acquire the monoclonal antibodies from the hybridomas, the hybridomas are cultured according to a conventional method after which the culture supernatant

is recovered, or else a method is used whereby the hybridomas are injected to a compatible mammalian animal, grown, and the ascites fluid is obtained. The former method is suited for obtaining high purity antibodies, while the latter method is suited for mass production of the antibodies.

The monoclonal antibodies obtained by these methods may then be purified to a high degree using conventional purification means, such as salting-out, gel filtration, affinity chromatography or the like.

The monoclonal antibodies prepared in this manner may then be checked for high sensitivity and high purity recognition of the antigen by common immunological means such as radioimmunoassay (RIA), enzyme-linked immunoassay, (EIA, ELISA), the fluorescent antibody technique (immunofluorescence analysis), etc.

The monoclonal antibodies used according to the invention are not limited to monoclonal antibodies produced by hybridomas, and they may be ones which have been artificially modified for the purpose of lowering the heteroantigenicity against humans. For example, a chimeric antibody may be used which consists of the variable region of a monoclonal antibody of a mammalian animal other than human, such as a mouse, and the constant region of a human antibody, and such a chimeric antibody may be produced by a known chimeric antibody-producing method, particularly a gene recombination technique.

Reshaped human antibodies may also be used according to the invention. These are prepared by using the complementary determinant region of a mouse or other non-human mammalian animal antibody to replace the complementary determinant region of a human antibody, and conventional gene recombination methods therefor are well-known. One of the known methods may be used to obtain a reshaped human antibody which is useful according to the invention. A preferred example of such

a reshaped human antibody is hPM-1 (see Intl. Unexamined Patent Application No. WO92-19759).

When necessary, amino acids of the framework (FR) region of the variable region of an antibody may be substituted so that the complementary determinant region of the reshaped human antibody forms a suitable antibody binding site (Sato et al., Cancer Res. 53:851-856, 1993). In addition, the object stated above may also be achieved by constructing a gene coding for an antibody fragment which binds to the antigen to inhibit IL-6 activity, such as Fab or Fv, or a single chain Fv (scFv) wherein the Fv of the H and L chains are attached via an appropriate linker, and using it for expression in appropriate host cells (see, for example, Bird et al., TIBTECH, 9:132-137, 1991; Huston et al., Proc. Natl. Acad. Sci. USA, 85:5879-5883, 1988).

Modified IL-6 used according to the invention may be the one disclosed by Brakenhoff et al, J. Biol. Chem. 269:86-93, 1994 or Savino et al., EMBO J. 13:1357-1367, 1994.

The modified IL-6 used may be obtained by introducing a mutation such as a substitution, deletion or insertion into the IL-6 amino acid sequence to maintain the binding activity with IL-6R while eliminating the IL-6 signal transfer function. The IL-6 source may be from any animal species so long as it has the aforementioned properties, but in terms of antigenicity, a human derived one is preferably used.

Specifically, the secondary structure of the IL-6 amino acid sequence may be predicted using a publicly known molecular modeling program such as WHATIF (Vriend et al., J. Mol. Graphics, 8:52-56, 1990), whereby the influence of mutated amino acid residues on the entire structure may also be evaluated. After determining appropriate mutated amino acid residues, a vector containing the nucleotide sequence coding for the human IL-6 gene is used as a template for introduction of the

mutation by the conventionally employed PCR (polymerase chain reaction) method, to obtain a gene coding for the modified IL-6. This is then incorporated into a suitable expression vector if necessary and expressed in *E. coli* cells or mammalian cells, and then used either while in the culture supernatant or after isolation and purification by conventional methods, to evaluate the binding activity for IL-6R and the neutralized IL-6 signal transfer activity.

An IL-6 partial peptide or IL-6R partial peptide used according to the present invention may have any sequence so long as it binds to IL-6R or IL-6, respectively, and has no IL-6 activity transfer function. IL-6 partial peptides and IL-6R partial peptides are described in U.S. Patent Publication No. US5210075. An IL-6 antisense oligonucleotide is described in Japanese Patent Application No. 5-300338.

A pharmaceutical composition for treatment of chronic rheumatoid arthritis whose effective component is an IL-6 antagonist according to the invention is effective for treatment of chronic rheumatoid arthritis if it blocks IL-6 signal transduction and suppresses abnormal growth of synovial cells induced by IL-6, which are implicated in the disease. Example 1 demonstrates the *in vitro* growth suppressing effect on rheumatic patient-derived synovial cells. In Example 2, IL-6 receptor antibody was administered to mice arthritic models immunized with type II collagen, and the relevant data demonstrates (1) suppression of onset of arthritis on the basis of an arthritis index (Fig. 4), (2) suppression of anti-type II collagen antibody production in the blood of collagen-immunized mice (Fig. 5) and (3) suppression of granulation tissue invasion into cartilage and bone (chronic proliferative synovitis) in the hind paw joints of mice arthritic models administered IL-6 receptor antibody (Fig. 6).

In regard to (1) and (2) above, the results confirmed a suppressing effect by IL-6 receptor antibody, especially initially, on onset of arthritis in the mice models. The results of (3) demonstrated that invasion of granulation tissue into the cartilage and bone tissue is suppressed, and this supports the results obtained in Example 1 (*in vitro* inhibition of synovial cell growth).

The experimental results of (1) and (2) indicate that the pharmaceutical composition for treatment of chronic rheumatoid arthritis of the present invention has an excellent initial effect on rheumatoid arthritis.

The pharmaceutical composition for treatment of chronic rheumatoid arthritis of the invention is preferably administered parenterally, for example by intravenous, intramuscular, intraperitoneal or subcutaneous injection, either systemically or locally. Also, it may be in the form of a medical formulation kit together with at least one type of medical carrier or diluent.

The dosage of the pharmaceutical composition for treatment of chronic rheumatoid arthritis of the invention when administered to humans will differ depending on pathological condition and age of the patient, and the mode of administration, and thus suitable and appropriate doses must be selected. As an example, a maximum of 4 divided doses in the range of about 1 to 1000 mg/patient may be selected. However, the pharmaceutical composition for treatment of rheumatoid arthritis of the invention is not limited to these dosages.

The pharmaceutical composition for treatment of rheumatoid arthritis of the invention may be formulated according to conventional methods. For example, an injection formulation is prepared by dissolving the purified IL-6 antagonist in a solvent such as physiological saline or a buffer solution and then adding

an adsorption inhibitor such as Tween 80, gelatin, human serum albumin (HSA) or the like, and the mixture may be lyophilized prior to use for solution reconstitution. The excipient used for lyophilization may be a sugar alcohol such as mannitol or glucose, or a saccharide.

#### EXAMPLES

The present invention will now be explained in more detail by way of the following examples, reference examples and experimental examples, with the understanding that the invention is in no way restricted thereto.

#### Reference Example 1. Preparation of human soluble IL-6 receptor

Soluble IL-6R was prepared (Yasukawa et al., J. Biochem. 108:673-676, 1990) by the PCR (polymerase chain reaction) method using plasmid pBSF2R.236 containing cDNA coding for human IL-6 receptor (IL-6R) obtained according to the method of Yamasaki et al. (Science, 241:825-828, 1988).

The aforementioned plasmid pBSF2R.236 was digested with restriction enzyme SphI to obtain an IL-6R cDNA fragment which was then inserted into mpl8 (Amersham Co.). The synthetic oligoprimers ATATTCTCTAGAGAGATTCT designed for introduction of a stop codon in IL-6R cDNA was used to introduce a mutation in the IL-6R cDNA by the PCR method using an Invitro Mutagenesis System (Amersham Co.). This procedure resulted in introduction of a stop codon at the position of amino acid 345 to obtain cDNA coding for soluble IL-6R (sIL-6R).

In order to express the sIL-6R cDNA in CHO cells, the aforementioned sIL-6R cDNA cut with HindIII-SalI was inserted into plasmid pECEDhfr (Clauser et al., Cell, 45:721-735, 1986) which had cDNA coding for dihydrofolate reductase (dhfr) inserted at the restriction enzyme PvuI cleavage site, to obtain the CHO cell expression plasmid pECEDhfr344.

A 10 µg of plasmid pECEDhfr344 was used for



transfection of the dhfr<sup>r</sup>CHO cell line DXB-11 (Urland et al., Proc. Natl. Acad. Sci. USA 77, 4216-4220, 1980) by the calcium phosphate precipitation method (Chen et al., Mol. Cell. Biol. 7:2745-2751, 1987).

5           The transfected CHO cells were cultured for 3 weeks in a nucleoside-free  $\alpha$ MEM selective culture medium containing 1 mM glutamine, 10% dialyzed Fetal Calf Serum (FCS), 100 U/ml penicillin and 100  $\mu$ g/ml streptomycin. The selected CHO cells were screened by the limiting  
10       dilution method, and a single monoclonal CHO cell line was obtained. The CHO cell clone was amplified in 20 nM to 200 nM concentration methotrexate (MTX), to obtain the human sIL-6R-producing CHO cell line 5E27.

          The CHO cell line 5E27 was cultured in Iscove's  
15       modified Dulbecco's medium (IMDM, product of Gibco Co.) containing 5% FCS, the culture supernatant was recovered, and the sIL-6R concentration in the culture supernatant was measured by the ELISA (Enzyme-Linked Immunosorbent Assay) method according to the common procedure.

20           Reference Example 2. Preparation of human IL-6 antibody

          Human IL-6 antibody was prepared according to the method of Matsuda et al. (Eur. J. Immunol. 18:951-956, 1988).

25           BALB/c mice were immunized with 10  $\mu$ g of recombinant IL-6 (Hirano et al., Immunol. Lett., 17:41, 1988) together with Freund's complete adjuvant, and this was continued once a week until anti-IL-6 antibodies were detected in the blood serum.

30           Immunocytes were extracted from the local lymph nodes, and polyethylene glycol 1500 was used for fusion with the myeloma cell line P3U1. Hybridomas were selected according to the method of Oi et al. (Selective Methods in Cellular Immunology, W.H. Freeman and Co., San  
35       Francisco, 351, 1980) using HAT culture medium, and a human IL-6 antibody-producing hybridoma line was

established. The human IL-6 antibody-producing hybridoma was subjected to IL-6 binding assay in the following manner.

Specifically, a soft polyvinyl 96-well microplate (product of Dynatech Laboratories, Inc., Alexandria, VA) was coated overnight with 100  $\mu$ l of goat anti-mouse Ig antibody (10  $\mu$ l/ml, product of Cooper Biomedical, Inc., Malvern, PA) in a 0.1 M carbonate-hydrogen carbonate buffer solution (pH 9.6) at 4°C. The plate was then treated for 2 hours at room temperature with PBS containing 100  $\mu$ l of 1% bovine serum albumin (BSA). After washing with PBS, 100  $\mu$ l of hybridoma culture supernatant was added to each well, and incubation was conducted overnight at 4°C.

The plates were then washed and  $^{125}$ I-labelled recombinant IL-6 was added to each well to 2000 cpm/0.5 ng/well, and after washing, the radioactivity of each well was measured with a gamma counter (Beckman Gamma 9000, Beckman Instruments, Fullerton, CA). Of 216 hybridoma clones, 32 hybridoma clones were positive for the IL-6 binding assay. Among these clones there was finally obtained the stable clone MH166.BSF2. The IL-6 antibody MH166 produced by this hybridoma has an IgG1K subtype.

The IL-6-dependent mouse hybridoma cell line MH60.BSF2 (Matsuda et al., Eur. J. Immunol. 18:951-956, 1988) was then used to determine the neutralizing activity of MH166 antibody on growth of the hybridoma. MH60.BSF2 cells were dispensed at an amount of  $1 \times 10^4$ /200  $\mu$ l/well, a sample containing MH166 antibody was added thereto, culture was performed for 48 hours, and 15.1 Ci/mmol of  $^3$ H-thymidine (New England Nuclear, Boston MA) was added, after which culture was continued for 6 hours.

The cells were placed on glass filter paper and treated with an automatic harvester (Labo Mash Science

Co., Tokyo, Japan). Rabbit anti-IL-6 antibody was used as a control. As a result, MH166 antibody inhibited uptake of  $^3\text{H}$ -thymidine by the MH60.BSF2 cells in a dose-dependent manner. This demonstrated that MH166 antibody neutralizes IL-6 activity.

Reference Example 3. Preparation of human IL-6 receptor antibody

Anti-IL-6R antibody MT18 constructed by the method of Hirata et al. (J. Immunol., 143:2900-2906, 1989) was bound to Sepharose 4B (product of Pharmacia Fine Chemicals, Piscataway, NJ) activated with CNBr, according to the accompanying instructions, and the bound complex was used to purify IL-6R (Yamasaki et al., Science 241:825-828, 1988).

The human myeloma cell line U266 was solubilized with 1 mM p-paraaminophenylmethane sulfonylfluoride hydrochloride (product of Wako Chemicals) containing 1% digitonin (product of Wako Chemicals), 10 mM triethanolamine (pH 7.8) and 0.15 M NaCl (digitonin buffer solution), and mixed with MT18 antibody bound to Sepharose 4B beads. The beads were then washed 6 times with digitonin buffer solution to obtain partially purified IL-6R for immunization.

BALB/c mice were immunized 4 times every 10 days with the partially purified IL-6R obtained from  $3 \times 10^9$  U266 cells, and then hybridomas were prepared by conventional methods. The culture supernatants of the hybridomas from the growth-positive wells were examined for IL-6 binding activity by the following method. After labelling  $5 \times 10^7$  U266 cells with  $^{35}\text{S}$ -methionine (2.5 mCi) they were solubilized with the aforementioned digitonin buffer solution. The solubilized U266 cells were mixed with a 0.04 ml of MT18 antibody bound to Sepharose 4B beads, and after washing 6 times with digitonin buffer solution, the  $^{35}\text{S}$ -methionine-labelled IL-6R was washed off with 0.25 ml of digitonin buffer solution (pH 3.4)

and neutralized with 0.025 ml of 1 M Tris (pH 7.4).

5 A 0.05 ml of the hybridoma culture supernatant was mixed with 0.01 ml of Protein G Sepharose (product of Pharmacia). After washing, the Sepharose was incubated with 0.005 ml of the <sup>35</sup>S-labelled IL-6R solution prepared earlier. The immunoprecipitated substance was analyzed by SDS-PAGE, and the hybridoma culture supernatants reacting with IL-6R were examined. As a result, a reaction-positive hybridoma clone PM-1 was established. 10 The IL-6R antibody PM-1 produced by hybridoma PM-1 has an IgG1K subtype.

The inhibiting activity of the antibody produced by hybridoma PM-1 against binding of IL-6 to human IL-6R was investigated using the human myeloma cell line U266. 15 Human recombinant IL-6 was prepared with *E. coli* (Hirano et al., Immunol. Lett., 17:41, 1988) and <sup>125</sup>I-labelled with Bolton-Hunter reagent (New England Nuclear, Boston, MA) (Taga et al., J. Exp. Med. 166:967, 1987).

4 x 10<sup>5</sup> U266 cells were cultured at room temperature 20 in the presence of a 100-fold excess of non-labelled IL-6 for one hour, together with 70% (v/v) of hybridoma PM-1 culture supernatant and 14000 cpm of <sup>125</sup>I-labelled IL-6. A 70 µl sample was overlaid onto 300 µl of FCS placed in a 400 µl microfuge polyethylene tube, and after 25 centrifugation the radioactivity on the cells was measured.

As a result it was demonstrated that the antibodies produced by hybridoma PM-1 inhibited binding of IL-6 to IL-6R.

30 Reference Example 4. Preparation of mouse IL-6  
receptor antibody

Monoclonal antibodies against mouse IL-6 receptor were prepared by the method described in Japanese Patent Application No. 6-134617.

35 Following the method of Saito et al. (J. Immunol., 147, 168-173, 1993), CHO cells producing mouse soluble

IL-6 receptor were cultured in IMDM medium containing 10% FCS, and the mouse soluble IL-6 receptor was purified from the culture supernatant using the mouse soluble IL-6 receptor antibody RS12 (see *ibid.* Saito et al.) and an affinity column immobilizing Affigel 10 gel (Biorad).

A 50 µg of the obtained mouse soluble IL-6 receptor was mixed with Freund's complete adjuvant and intraperitoneally injected into Wistar rats (Nihon Charles River Co.). Booster immunizations were given with Freund's incomplete adjuvant after 2 weeks. On the 45th day the rats were butchered, and about  $2 \times 10^8$  splenic cells thereof were used for cell fusion with  $1 \times 10^7$  mouse P3U1 myeloma cells by a conventional method utilizing 50% PEG1500 (Berlinger Mannheim), after which the hybridomas were screened with HAT medium.

After adding the hybridoma culture supernatants to an immunoplate coated with rabbit anti-rat IgG antibody (Cappel Co.), mouse soluble IL-6 receptor was reacted therewith and the hybridomas producing antibodies against mouse soluble IL-6 receptor were screened by the ELISA method using rabbit anti-mouse IL-6 receptor antibody and alkali phosphatase-labelled sheep anti-rabbit IgG. The hybridoma clones in which antibody production was confirmed were subjected to subscreening twice to obtain a single hybridoma clone. This clone was named MR16-1.

The neutralizing activity of the antibody produced by this hybridoma against mouse IL-6 signal transduction was investigated by incorporation of  $^3\text{H}$ -thymidine using MH60.BSF2 cells (Matsuda et al., *J. Immunol.* 18, 951-956, 1988), MH60.BSF2 cells were added to a 96-well plate to  $1 \times 10^4$  cells/200 µl/well, and then mouse IL-6 (10 pg/ml) and MR16-I antibody or RS12 antibody were added to 12.3-1000 ng/ml prior to culturing at 37°C, in 5% CO<sub>2</sub> for 44 hours, after which  $^3\text{H}$ -thymidine (1 µCi/well) was added and the uptake after 4 hours was measured. As a result, MR16-1 antibody was found to inhibit uptake of  $^3\text{H}$ -

thymidine by MH60.BSF2 cells.

Experiment 1. Establishment of chronic rheumatoid  
arthritis-derived synovial cell line

(1) Preparation of synovial cells

5               Synovial tissue was obtained during surgical  
operation on the joint of a chronic rheumatoid arthritis  
patient. The synovial tissue was minced with scissors  
and then subjected to enzymatic dissociation by  
incubation for one hour at 37°C with 5 mg/ml of TYPE I  
10 collagenase (product of Sigma Chemical Co.) and 0.15  
mg/ml of bovine pancreatic DNase (product of Sigma  
Chemical Co.) in IMDM (Iscove's modified Dulbecco's  
medium), and passed through a mesh to obtain single  
cells. These obtained cells were then cultured overnight  
15 in a culture flask using IMDM containing 5% FCS, after  
which the non-adherent cells were removed to obtain the  
synovial cells. The synovial cells were passaged 3 to 6  
times and used for the following experiment.

(2) IL-6 production by synovial cells

20               The synovial cells obtained as described above  
were suspended in IMDM culture medium containing 5% FCS  
(product of Hyclone Laboratories Inc.), 10 U/ml of  
penicillin G and 100 µg/ml streptomycin to an amount of  $3 \times 10^3$  cells/well, and were then cultured in 96-well  
25 microtiter plate (product of Falcon Co.), which human  
interleukin-1β (IL-1β), human tumor necrosis factor α  
(TNFα), human platelet-derived growth factor (PDGF)AB and  
human basic fibroblast growth factor (bFGF) were added to  
concentrations of 0.01 or 0.1, 0.1 or 1, 1 or 10 and 1 or  
30 10 ng/ml, respectively, and upon culturing at 37°C for 72  
hours the culture supernatants were collected.

              A 100 µl of anti-human IL-6 antibody MH166 (1  
µg/ml) was added to a 96-well ELISA plate (Immunoplate:  
product of Nunc Co.) and incubated at 4°C for 24 hours.  
35 Each well was subsequently washed with PBS containing  
0.05% Tween20, and blocked at 4°C overnight with PBS

08817084-0409  
462040-48021880

containing 1% BSA. The culture supernatants obtained previously were then diluted with PBS containing 1% BSA, added to the wells, and then incubated at room temperature for 2 hours. After washing with PBS containing 0.05% Tween20, 2.5 µg/ml of rabbit polyclonal anti-human IL-6 antibody purified with a 100 µl protein A column (product of Pharmacia) was added.

After incubating at room temperature for 2 hours, the rabbit polyclonal anti-IL-6 antibody binding to IL-6 in the culture supernatants was reacted with alkali phosphatase-bound anti-rabbit IgG antibody (product of Tago Co.). And then 1 mg/ml of Sigma104 alkali phosphatase substrate (product of Sigma Co.) was added according to the attached instructions and the absorbance at 405-600 nm was measured with an MPR A4 microplate reader (product of Tosoh Co.).

Calibration curves were prepared for the recombinant IL-6 during each assay for conversion of the absorbance OD values to human IL-6 concentrations. The results are given in Table 1.

Table 1

Augmented IL-6 production from synovial cell

Treatment (ng/ml)	IL-6 (ng/ml)
Untreated	0.096 ±0.012
IL-1β 0.01 0.1	6.743 ±0.178 17.707 ±0.259
TNFα 0.1 1	0.575 ±0.008 1.688 ±0.034
PDGF-AB 1 10	0.163 ±0.035 0.165 ±0.016
bFGF 1 10	0.181 ±0.009 0.230 ±0.019

Note: The synovial cells were cultured for 3 days with IL-1β, TNFα, PDGF-AB or bFGF. After culture, the IL-6 concentrations of the supernatants were measured by ELISA.

The results demonstrated that IL-1 $\beta$  strongly promotes IL-6 production by synovial cells.

Example 1.

(1) The synovial cells obtained in Experiment 1 (3 x 10<sup>3</sup>/well) were suspended in IMDM culture medium containing 5% FCS (product of Hyclone Laboratories, Inc.), 10 U/ml of penicillin G and 100  $\mu$ g/ml of streptomycin and were then added into a 96-well microtiter plate (#3072, product of Falcon Co.) and cultured for 5 days in the presence of various concentrations of IL-6 or sIL-6 alone, or in the presence of both IL-6 and sIL-6R. At 72 hours after starting the culturing, <sup>3</sup>H-thymidine (product of Amersham International plc) was added to each well to 1  $\mu$ Ci/well, and after the culturing was completed the radioactivity in the cells was measured with a scintillation counter. The results are shown in Fig. 1.

As a result, the <sup>3</sup>H-thymidine uptake of the synovial cells was low with IL-6 or sIL-6R alone, and no growth of synovial cells was observed. In contrast, in the presence of at least a 10 ng/ml concentration of IL-6 and 100 ng/ml concentration of sIL-6R, significant uptake of <sup>3</sup>H-thymidine was observed compared to the control group. Thus, while virtually no growth effect on synovial cells was exhibited with IL-6 alone, in the presence of both IL-6 and sIL-6R a powerful synovial cell growth effect was clearly produced.

(2) Synovial cells (3 x 10<sup>3</sup>/well) were cultured in the presence of a sufficient amount of IL- $\beta$  to produce IL-6 (0.1 ng/ml), 100 ng/ml of sIL-6R and 25  $\mu$ g/ml of IL-6 antibody or 25  $\mu$ g/ml of IL-6R antibody. At 72 hours after the start of culturing, <sup>3</sup>H-thymidine was added to each well to 1  $\mu$ Ci/well, and after the culture was completed the radioactivity in the cells was measured with a scintillation counter. The results are shown in Fig. 2. Addition of IL-6 antibody or IL-6R antibody



completely suppressed the growth of synovial cells augmented by sIL-6R.

(3) Synovial cells ( $3 \times 10^3$ /well) were cultured in the presence of 100 ng/ml of IL-6 (product of Genzyme Co.), 100 ng/ml of sIL-6R and 25 µg/ml of IL-6 antibody or IL-6R antibody, which were obtained in the above-mentioned Reference Examples. At 72 hours after the start of culture,  $^3\text{H}$ -thymidine was added to each well to 1 µCi/well, and after the culture was completed, the radioactivity in the cells was measured with a scintillation counter. The results are shown in Fig. 3. Addition of IL-6 antibody or IL-6R antibody completely suppressed the growth of synovial cells augmented by sIL-6R.

Example 2.

The suppressing effect of IL-6 receptor antibody on onset of arthritis was investigated using a mouse arthritis model.

A bovine type II collagen solution (Collagen Technology Research Group) (4 mg/ml) dissolved in a 0.1 N aqueous acetic acid solution and complete adjuvant H37Ra (DIFCO) were mixed in equivalent amounts, to prepare an adjuvant. A 100 µl of the adjuvant was subcutaneously injected at the base of tail of 8- to 9-week-old female DBA/1J mice (Charles River Japan). An additional 100 µl was injected 20 days later under the dorsal skin to induce arthritis.

Mouse IL-6 receptor antibody MR16-1 was intravenously administered at 2 mg per mouse upon first collagen sensitization, and each mouse was subcutaneously injected with an additional 0.5 mg (n=5) each week thereafter for 7 weeks. As a control, anti-DNP antibody KH-5 (Chugai Seiyaku) of the same isotype was used (n=5).

The severity of arthritis was evaluated based on an arthritis index. The evaluation was based on a 4 point scale for each limb, for a total of 16 points per

individual. The evaluation standard was as follows.

0.5: Erythema observed at one site of joint.

1: Erythema observed at two sites of joint, or redness but no swelling of dorsa.

5 2: Moderate swelling observed.

3: Severe swelling of pedal dorsa, but not reaching all of the digits.

4: Severe swelling of pedal dorsa and digits.

The results are shown in Fig. 4. Onset of arthritis  
10 from early stage arthritis was clearly suppressed in the IL-6 receptor antibody-administered group, compared to the control antibody-administered group.

On the other hand, the results of measurement of the anti-type II collagen antibody titer in the mouse blood  
15 showed a significant reduction from early stage arthritis in the IL-6 receptor antibody-administered group compared to the control antibody-administered group (Fig. 5).

The mice were sacrificed on the 35th day after collagen immunization, and the hind legs were fixed with  
20 20% formalin. They were then subjected to demineralization in an EDTA solution (pH 7.6) and dewatering with alcohol. They were subsequently wrapped in paraffin and cut to 2  $\mu$ m thick sections. The sections were stained with hematoxylin and eosin and observed  
25 under 125x magnification (Fig. 6). As a result, invasion of granulation tissue into the cartilage and bone, i.e. chronic proliferative synovitis was suppressed in the IL-6 receptor antibody-administered group compared to the control antibody-administered group.

30 IL-6 is a cytokine which induces differentiation of B cells into antibody-producing cells. IL-6 also promotes proliferation of synovial cells in the presence of IL-6 receptor. Since in mouse collagen arthritis models, anti-IL-6 receptor antibody significantly  
35 suppressed anti-type II collagen antibody titers on the 21st and 35th days after collagen sensitization, compared to the control antibody-administered group, it is

08817084-04079

believed that the antibody production inhibition by anti-IL-6 receptor antibody is one factor responsible for the suppressing effect on arthritis. Moreover, although no suppression of antibody production was observed from the 49th day after collagen sensitization, the fact that an adequate suppressing effect on onset of arthritis was exhibited even during this period, and that HE staining of tissue surrounding the tarsal bone showed suppressed invasion of granulation tissue into the cartilage and bone of the anti-IL-6 receptor antibody-administered group compared to the control group, the synovial growth-suppressing effect is also believed to contribute to the arthritis-inhibiting effect.

#### INDUSTRIAL APPLICABILITY

Synovial cells from chronic rheumatoid arthritis patients proliferate in the presence of both IL-6 and sIL-6R. The fact that synovial fluid of chronic rheumatoid arthritis patients contains a sufficient amount of IL-6 and sIL-6R to induce growth of synovial cells suggests that signal transduction by IL-6 is involved in abnormal growth of synovial cells in chronic rheumatoid arthritis.

It has thus been conclusively demonstrated that a chronic rheumatoid arthritis therapy whose effective component is an IL-6 antagonist according to the present invention suppresses growth of synovial cells in chronic rheumatoid arthritis patients in the presence of IL-6 and sIL-6R, and thus has a therapeutic effect against chronic rheumatoid arthritis. Consequently, the IL-6 antagonist of the invention is useful as a therapeutic agent for chronic rheumatoid arthritis in which abnormal growth of synovial cells occurs.

1. A pharmaceutical composition for treatment of chronic rheumatoid arthritis containing an interleukin-6 antagonist as an effective component.

2. A pharmaceutical composition for treatment of chronic rheumatoid arthritis according to claim 1, characterized in that said interleukin-6 antagonist suppresses abnormal growth of synovial cells occurring with chronic rheumatoid arthritis.

3. A pharmaceutical composition for treatment of chronic rheumatoid arthritis according to claim 1, characterized in that said interleukin-6 antagonist is an antibody against interleukin-6.

4. A pharmaceutical composition for treatment of chronic rheumatoid arthritis according to claim 2, characterized in that said interleukin-6 is human interleukin-6.

5. A pharmaceutical composition for treatment of chronic rheumatoid arthritis according to claim 1, characterized in that said interleukin-6 antagonist is an antibody against interleukin-6 receptor.

6. A pharmaceutical composition for treatment of chronic rheumatoid arthritis according to claim 2, characterized in that said interleukin-6 receptor is human interleukin-6 receptor.

7. A synovial cell growth inhibitor containing an interleukin-6 antagonist as an effective component.

8. A synovial cell growth inhibitor according to claim 7, characterized in that said interleukin-6 antagonist is interleukin-6 antibody or interleukin-6 receptor antibody.

## SUMMARY

5

10

## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CHRONIC RHEUMATOID ARTHRITIS THERAPY CONTAINING IL-6 ANTAGONIST AS

EFFECTIVE COMPONENT

the specification of which (check one)

☐ is attached hereto

☒ was filed on June 7, 1995 as International Application Serial No. PCT/JP95/01144 and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in Title 37, Code of Federal Regulations § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

## PRIOR FOREIGN APPLICATION(S)

NUMBER	COUNTRY	DAY/MONTH/YEAR FILED	PRIORITY CLAIMED
6-244035(Pat. Appln.)	Japan	7/October/1994	Yes


☒ I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:


APPLICATION SERIAL NO.	FILING DATE	STATUS: PATENTED, PENDING, ABANDONED


I hereby appoint as my attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Stephen A. Bent, Reg. No. 29,768; David A. Blumenthal, Reg. No. 26,257; John J. Feldhaus, Reg. No. 28,822; Donald D. Jeffery, Reg. No. 49,980; Peter G. Mack, Reg. No. 26,001; Brian J. McNamara, Reg. No. 32,789; Sybil Meloy, Reg. No. 22,749; George E. Quillin, Reg. No. 32,792; Colin G. Sandercock, Reg. No. 31,298; Bernhard D. Saxe, Reg. No. 28,665; Richard L. Schwaab, Reg. No. 25,479; Arthur Schwartz, Reg. No. 22,115; Harold C. Wegner, Reg. No. 25,258.


Send all correspondence to POLEY & LARDNER, Washington Harbour, 3000 K Street, N.W., Suite 500, P.O. Box 25696, Washington, D.C. 20007-8696. Address telephone communications to Harold C. Wegner at (202) 672-5300.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First or Sole Inventor <u>Tadamitsu Kishimoto</u>	Signature of First or Sole Inventor 	Date March 28, 1997
Residence Address <u>Tondabayashi-shi, Osaka, Japan</u>	Country of Citizenship Japan	
Post Office Address 3-5-31, Nakano-cho, Tondabayashi-shi, Osaka 584 Japan		

Full Name of Second Inventor <u>Masahiko Mihara</u>	Signature of Second Inventor 	Date March 28, 1997
Residence Address <u>Gotenba-shi, Shizuoka, Japan</u> SPX	Country of Citizenship Japan	
Post Office Address c/o CHUGAI SEIYAKU KABUSHIKI KAISHA 135, Komakado 1-chome, Gotenba-shi, Shizuoka, Japan		

Full Name of Third Inventor <u>Yoichiro Moriya</u>	Signature of Third Inventor 	Date March 28, 1997
Residence Address <u>Gotenba-shi, Shizuoka, Japan</u> SPX	Country of Citizenship Japan	
Post Office Address c/o CHUGAI SEIYAKU KABUSHIKI KAISHA 135, Komakado 1-chome, Gotenba-shi, Shizuoka, Japan		

Full Name of Fourth Inventor <u>Yoshiyuki Ohsugi</u>	Signature of Fourth Inventor 	Date March 28, 1997
Residence Address <u>Gotenba-shi, Shizuoka, Japan</u> SPX	Country of Citizenship Japan	
Post Office Address c/o CHUGAI SEIYAKU KABUSHIKI KAISHA 135, Komakado 1-chome, Gotenba-shi, Shizuoka, Japan		

Full Name of Fifth Inventor	Signature of Fifth Inventor	Date
Residence Address	Country of Citizenship	
Post Office Address		

Full Name of Sixth Inventor	Signature of Sixth Inventor	Date
Residence Address	Country of Citizenship	
Post Office Address		

Full Name of Seventh Inventor	Signature of Seventh Inventor	Date
Residence Address	Country of Citizenship	
Post Office Address		

Fig.1






Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig.6  
(a)



(b)

